Kornimate/medical-research-clean huggingface dataset:
biomarker profiling in individuals at risk for prion disease

Conditions: CJD (Creutzfeldt Jakob Disease); Prion Diseases; GSS; FFI; Familial Fatal Insomnia

Summary: we are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. we hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the direction of future clinical trials.

this study aims to measure biomarkers longitudinally in individuals at risk of developing genetic prion disease to identify clinical assays and molecular markers that: can inform our understanding of pre-clinical pathology, predict timing of disease onset in pre-symptomatic individuals, and enable development and evaluation of novel treatment efficacy in pre-symptomatic or early symptomatic individuals. participation in the study involves annual visits to the clinic site in charlestown, ma. study visits include: a medical exam, blood draws, cognitive tests and questionnaires, spinal fluid collection, and (optional) mri. travel support and stipend is provided for interested individuals.

Eligibility criteria:
inclusion criteria: 1. aged 18 - 85, 2. one of the following: 1. known carrier of pathogenic prnp mutation 2. history of probable or definite prion disease in biological parent and other family members 3. medically safe to undergo blood draw, lumbar puncture and cognitive testing, 4. adequate visual and auditory acuity to complete cognitive testing, 5. fluent in english, 6. at least 5 years of education, 7. capable of providing informed consent and following study procedures. exclusion criteria: 1. any cns disease other than asymptomatic or early prion disease, such as clinical stroke, brain tumor, multiple sclerosis, significant head trauma with persistent neurological or neurocognitive deficits, alzheimer's disease, parkinson's disease, frontotemporal lobar degeneration or other known neurodegenerative disease, 2. history of alcohol or other substance abuse or dependence within the past two years, 3. any significant systemic illness or unstable medical condition or pregnancy that could represent safety risk or affect participation in the study, 4. coagulopathy or anti-coagulant therapy (such as coumadin) increasing the risk for phlebotomy or lumbar puncture resulting in pt/ptt and inr within 1.5 standard deviation over the upper normal limit.
frequency of putative enteric zoster diagnosed using saliva samples in patients with abdominal pain: a prospective study

Conditions: Abdominal Pain; Zoster With Other Complications

Summary: the aim of this study is to identify the frequency of enteric zoster using salivary varicella zoster virus (vzv) dna pcr in patients who visit the emergency room due to acute abdominal pain.

varicella zoster virus (vzv) infects and establishes latency in neurons in the ganglia of the cranial nerve, dorsal root, and enteric ganglia. vzv reactivation in enteric neurons (enteric zoster) can cause nonspecific abdominal pain and/or serious gastrointestinal dysfunction without cutaneous manifestations. detection of vzv dna in saliva may be useful for identifying enteric zoster. we evaluated the frequency of putative enteric zoster based on the presence of salivary vzv dna in patients with acute abdominal pain. adult patients who visited the emergency room due to moderate to severe acute abdominal pain were prospectively enrolled at a tertiary hospital between may 2019 and november 2019. abdominopelvic computed tomography (apct) was performed in all patients. saliva samples were collected from all studied patients. enteric zoster was suspected based on the presence of salivary vzv dna, detected using real-time polymerase chain reaction (pcr).

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18, and \< 80 years * er-visited patients with acute abdominal pain * numerical rating scale (nrs) score ≥ 4 * unresponsive to gastrointestinal motility drug, antacid exclusion criteria: * unwilling or unable to give informed consent forms * patients taking antiviral agents * patients complaining mild abdominal pain (nrs score ≤ 3)

Keywords: varicella zoster virus enteric zoster saliva
effect of doula in nulliparas and multiparas

Conditions: Labor Pain

Summary: psychological care during labor is considered as an important supplemental procedure for alleviating delivering stress and pain. although doula has been recommending that should be given for parturients, its precise effect on nulliparous and multiparous women is still unknown. the investigators hypothesized that multiparas had experienced the process of labor, but the nulliparas were not, so doula support would produce different effect on these two population.


Eligibility criteria:
inclusion criteria: * healthy term parturients * chinese * 19-45 years exclusion criteria: * organic dysfunction * participants younger than 19 years or older than 45 years * those who were not willing to or could not finish the whole study at any time * pregnancy-induced hypertension and diabetes mellitus

Keywords: doula psychological care labor analgesia
effect of stress ball on comfort and anxiety controlled trial

Conditions: Anxiety; Comfort

Summary: in this study, it was aimed to determine the anxiety levels and comfort levels of the patients using stress ball in patients receiving hemodialysis treatment. this study was conducted as a randomized controlled trial. the universe of the study consisted of 156 patients receiving hd treatment at a special hemodialysis center. the study was completed with a total of 63 patients, including 31 people in the intervention group and 32 people in the control group, who met the criteria for inclusion in the study between 27.02.2023 and 27.03.2023. the individual demonstration form was used to collect data, the visual analog scale (vas) for stress level and the hemodialysis comfort scale.

procedures administered to intervention groups: patients will be given written and oral consent by explaining the purpose of the study. patients with fistula and non-grafted arms will be asked to fill out data collection forms at the first interview. patients will then be asked to squeeze the stress ball 15 minutes before the start of hemodialysis treatment and for 15 minutes during hemodialysis treatment. this treatment will be performed during the 9 (nine) hemodialysis treatment. after the last session, data collection forms will be filled out again. use of stress ball 1) place a stress ball in one hand (which hand will be left to the patients' wishes.) 2.squeeze the ball in your hand for 2-3 seconds after receiving it and then loosen it. 3.perform this application for a total of 30 minutes before and during hemodialysis treatment. procedures administered to control groups: no intervention will be given to the control group other than standard treatment. data collection forms will be completed before the first dialysis session and after the ninth session.

Eligibility criteria:
inclusion criteria: * who is over 18 years old * having been on an average of four hours of hemodialysis program, three times a week, for at least 6 months; * who can respond in writing or verbally to the scales applied, * in addition to last-stage kidney disease, there is no physical deficiency, * can apply stress ball as shown during hemodialysis work * individuals who agree to participate in the research exclusion criteria: * with fistula on both arms * people with psychiatric problems * with nerve, soft tissue and vascular disease in the upper extremity * out of town during work

Keywords: hemodialysis, comfort, anxiety
a phase i study of the safety and immunogenicity of rgp 120/hiv-1iiib vaccine in hiv-1 seropositive adult volunteers

Conditions: HIV Infections

Summary: to test the safety and immunogenicity of rgp 120/hiv-1iiib vaccine in hiv-1 seropositive adult patients.


Eligibility criteria:
inclusion criteria patients must have the following: * stage 1 or 2 walter reed clinical staging of hiv infected individuals. * the ability to understand and sign a written informed consent form, which must be obtained prior to study entry. * be available for 24 weeks so that follow up may be completed. * qualify for care as department of defense health care beneficiary. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than hiv-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. concurrent medication: excluded: * corticosteroids or other known immunosuppressive drugs. * any experimental agents. patients with the following are excluded: * prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than hiv-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. prior medication: excluded within 30 days of study entry: * zidovudine or other anti-retroviral agents.

Keywords: vaccines, synthetic drug evaluation acquired immunodeficiency syndrome aids vaccines
readily available urinary sodium analysis in patients with acute decompensated heart failure

Conditions: Acute Decompensated Heart Failure

Summary: the goal of this clinical trial is to compare physician-guided (soc) versus nurse-led natriuresis-guided diuretic therapy in patients with acute decompensated heart failure (adhf). the main questions it aims to answer are: * difference in natriuresis and diuresis * feasibility of the protocol. participants will be asked to gather two 24 h urine collections. researchers will compare soc versus nurse-led diuretic titration to see if there is a difference in natriuresis after 48 hours.

the easy-hf study was a single-centre, randomized, open-label study comparing standard of care (soc) diuretic management at the treating physician's discretion with a nurse-led natriuresis-guided protocol in patients with adhf. a bedside sensor was used to measure the urinary sodium content.the primary endpoint was total natriuresis after 48 hours. secondary endpoints included safety profile and user-friendliness of both the protocol and the point-of-care sensor.

Eligibility criteria:
inclusion criteria: * older than 18 years * provide written informed consent * hospital admission with signs and symptoms of congestion warranting intravenous decongestive therapy * congestion score of at least 2 based upon the presence of edema, pleural effusion, or ascites * n-terminal pro-b-type natriuretic peptide (nt-probnp) level of at least 500 ng per litre (800 ng per litre in case of atrial fibrillation) exclusion criteria: * patients unable to collect a 48h-urine collection * estimated gfr below 20 ml/min/1.73m\^2 * concomitant diagnosis of an acute coronary syndrome * need for inotropic or vasopressor support * ventricular assist device * renal replacement therapy * treatment with intravenous loop diuretics \> 80mg furosemide or an equivalence of another loop diuretic (40mg furosemide = 1mg bumetanide) during the index hospitalization and prior to randomization

Keywords: acute decompensated heart failure natriuresis nurse-led diuretic therapy
application of somatostatin for advanced gastric cancer after d2 lymph node dissection

Conditions: Gastric Cancer After D2 Lymph Node Dissection

Summary: gastric cancer radical surgery related complications are common.somatostatin is a conventional medical therapy for bleeding.this study explore the effect of somatostatin for advanced gastric cancer after d2 lymph node dissection.


Eligibility criteria:
inclusion criteria: 1. more than eighteen years old 2. gastric cancer diagnosed by pathological examination 3. be given informed consent 4. without diabetes/hyperthyroidism/damages of functions of heart, liver and kidney/systemic infection/immunodeficiency exclusion criteria: 1. contraindication of vascular puncture operation 2. patients who refused to take part in the programe 3. poor compliance of treatment 4. malnutrition,bmi\<18 5. with pancreatectomy
clinico-immunological characterization and immune tolerance breakdown in hu-autoimmunity

Conditions: Immune Tolerance

Summary: phenotypic characterization of patients with hu-abs, including the different neurological presentation and the presence or not of an underlying cancer. analysis and clinical correlation of the diagnostic techniques for hu-abs detection (immunofluorescence, immunodot/western blot, and cba) in serum and/or csf. genomic and transcriptomic features of tumors (histological and immune infiltrate characteristics, transcriptomic profile, mutational status).


Eligibility criteria:
* inclusion criteria \* : * patient with neurological disorder * patient with hu antibody in sera or csf * exclusion criteria \* : * patient with no data * patient without neurological disorder * patient without hu antibody in sera/csf

Keywords: paraneoplastic neurological disorders lung cancer hu autoimmunity immune tolerance breakdown
a study to evaluate long-term maintenance treatment with once daily crisaborole ointment 2% in pediatric and adult participants with mild-to-moderate atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this study will evaluate crisaborole therapy once daily (qd) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (bid) treatment.

approximately 700 participants will be enrolled in an run-in period to receive crisaborole, bid for up to a maximum of 8 weeks to identify crisaborole responders. a responder is defined as a participant who achieves both isga and easi50 success. isga success is defined as achieving a score of 0 or 1 with at least 2 grade improvement from baseline; and the easi50 success is defined as at least 50% improvement from baseline. non responders at the end of the 8-week run-in period will be discontinued from the study. approximately 250 responders will be randomized (1:1 ratio) to enter the double-blind maintenance treatment period to receive crisaborole or vehicle qd for 52 weeks, with follow-up assessments every 4 weeks. if a flare occurs and if the participant meets the criteria for having a flare (isga ≥2), the participant will switch to enter a flare treatment period to receive open-label crisaborole bid for up to 12 weeks with follow-up assessments every 4 weeks. if the flare has resolved (isga ≤1) the participant will resume maintenance treatment and respective visit schedule. if a flare does not resolve after 3 consecutive treatment courses the participant will discontinue the study. a flare treatment period may comprise up to 3 consecutive treatment courses with crisaborole bid (each course is 4 weeks). an end of study (eos) safety follow-up is required 4 weeks after the last study treatment of any treatment period.

Eligibility criteria:
inclusion criteria: * male or female * 3 months of age and older * confirmed diagnosis of atopic dermatitis according to hanifin and rajka criteria * minimum of 5% bsa affected by atopic dermatitis * isga score of mild (2) or moderate (3) exclusion criteria: - has any clinically significant medical disorder, condition, or disease (including active or potentially recurrent non ad dermatological conditions and known genetic dermatological conditions that overlap with ad, such as netherton syndrome).

Keywords: eczema crisaborole
respiratory disease cohort studies of chinese medicine for asthma (research- asthma)

Conditions: Bronchial Asthma

Summary: the purpose of this study is to define the standard use of tcm treatment regimen as the tcm cohort group and the non-tcm cohort group of those who use conventional western medicine treatment without the standard tcm treatment regimen through a multi-center, large-sample prospective cohort study design. to evaluate the clinical efficacy and safety of tcm treatment regimens in the treatment of bronchial asthma, and to provide high-quality evidence for the promotion and application of tcm syndrome differentiation treatment in bronchial asthma.

bronchial asthma is characterized by chronic inflammation of the airways, which is often recurrent, long-lasting and difficult to cure. clinical studies have confirmed that the clinical symptoms and quality of life of asthma patients have been significantly improved after tcm intervention. however, most of the current clinical research methods on asthma are small-sample and rct studies, resulting in insufficient demonstration of efficacy, and there is an urgent need to carry out multi-center, large-sample, high-quality real-world studies in order to obtain higher quality evidence-based medical evidence. this is a multi-center, large-sample prospective cohort study, which will evaluate the clinical efficacy and safety of tcm treatment regimens in the treatment of bronchial asthma, and provide high-quality evidence for the promotion and application of tcm syndrome differentiation therapy in bronchial asthma. the cohort study will enroll 1508 patients, and the standard use of tcm treatment regimen will be set as the tcm cohort group, and those who will use the conventional treatment of western medicine but not the standard tcm treatment regimen will be the non-tcm cohort group. the asthma control rate was the main outcome index, and the asthma control questionnaire (acq), asthma quality of life score (aqlq), clinical symptom and sign score, lung function, exhaled nitric oxide, induced sputum inflammation phenotype, glucocorticoid dose, and fast-acting β2 agonist dose were the secondary outcome indicators. follow-up was conducted every 3 months for 1 year.

Eligibility criteria:
inclusion criteria: 1. patients who meet the diagnosis of bronchial asthma; 2. age 18\~80 years old; 3. have not participated in other clinical studies within 1 month before enrollment; 4. voluntarily participate in the study and sign the informed consent form. exclusion criteria: 1. patients with respiratory failure and mechanical ventilation during acute asthma exacerbation; 2. delirium, impaired consciousness, dementia, and various mental illnesses; 3. patients with other lung diseases such as copd, lung abscess, cystic fibrosis, bronchiectasis, etc., and severe liver and kidney diseases; 4. patients with neuromuscular diseases that affect respiratory motor function and are unable to complete the six-minute walk test; 5. pregnant and lactating patients; 6. those who are participating in other clinical trials.

Keywords: bronchial asthma asthma control rate number of acute attacks cohort studies
stableeyes with active neurofeedback

Conditions: Vestibular Disorder; Vestibular Schwannoma; Space Motion Sickness; Motion Sickness

Summary: the investigators have developed a self-administered rehabilitation tool that incrementally guides the user to increase head motion to mitigate motion sickness and enhance postural recovery following centrifugation or unilateral vestibular nerve deafferentation surgery.

the rehabilitation device guides users to perform sinusoidal head rotations, matched to a metronome, about the yaw, pitch, and roll axes (60 sec epochs, 5 minutes per axis, 15 min total). the assessment for each axis consists of the number of completed epochs with each epoch requiring head rotations of a different amplitude. subjects are instructed to begin with an 'easy' amplitude (i.e. small) and increase or decrease amplitude depending on the subject's perception of motion sickness - which is input from 0 (absent motion sick) to 11 (vomit) using a handheld controller. video-oculography captures eye and head velocity as well as tracks the number of blinks and saccades, metrics that can indicate worsening nausea.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. in good general health as evidenced by medical history or diagnosed with unilateral vestibular schwannoma 4. willing to adhere to the swan and/or vestibular rehabilitation regimen exclusion criteria: 1. current use of anti-nausea medication 2. presence of cervical spine pathology that limits head motion to \< 30 degrees in the horizontal or vertical plane (i.e. degenerative disc disease, rheumatoid arthritis) 3. any orthopedic pathology that prevents walking or standing independently (i.e. recent surgery) 4. legal blindness (20/200 or worse visual acuity) 5. treatment using a motion sickness investigational drug or other motion sickness behavioral intervention within 30 days
jupiter study: transapical aortic valve implantation for aortic regurgitation

Conditions: Aortic Stenosis; Aortic Insufficiency; Aortic Regurgitation

Summary: the purpose of this registry is to observe longterm performance and safety of the jenavalve tavi system, in routine medical and everyday conditions.

the objective of this study is to evaluate the long term safety and effectiveness of the ce-marked jenavalve system transapical in an elderly patient population with severe aortic stenosis and/or aortic insufficiency who are at high risk for open surgical aortic valve replacement. the target study population will consist of elderly patients suffering from severe symptomatic degenerative aortic valve stenosis and/or aortic insufficiency who show an increased risk for an open aortic valve replacement surgery due to existing co-morbidities.

Eligibility criteria:
inclusion criteria: * patients suitable for tavi with the jenavalve according to instructions for use exclusion criteria: * patients unsuitable for tavi with the jenavalve according to instructions for use
carbohydrate quality, quality of life, and menopausal symptoms in postmenopausal women

Conditions: Woman

Summary: this study aimed to evaluate the effect of carbohydrate quality on quality of life and menopausal symptoms in postmenopausal women. data were collected from 604 postmenopausal women using a demographic questionnaire, the menopause-specific quality of life questionnaire (menqol), and the menopause rating scale (mrs). carbohydrate quality was assessed using food frequency consumption data, and the results were analyzed with spss 24 software.

objective: this study aimed to evaluate the effect of carbohydrate quality on quality of life and menopausal symptoms in postmenopausal women. method: a total of 604 postmenopausal women participated in the study. participants completed a demographic questionnaire, the menopause-specific quality of life questionnaire (menqol), and the menopause rating scale (mrs). carbohydrate quality was assessed using food frequency consumption data and analyzed based on dietary fiber, glycemic index, solid carbohydrate-to-total carbohydrate ratio, and whole grains-to-total grains ratio. results were divided into five quartiles, with q5 representing the highest and q1 the lowest carbohydrate quality. data analysis was conducted using spss 24 software.

Eligibility criteria:
inclusion criteria: * women who have not menstruated for 12 consecutive months and have no intermenstrual bleeding * aged between 30 and 90 years * must be willing to volunteer exclusion criteria: * women diagnosed with any psychological disorder * cancer patients

Keywords: carbohydrate quality quality of life menopausal symptoms